Skip to main content
Search

Hidradenitis suppurativa: current understanding and management

Published on January 31, 2023   24 min

A selection of talks on Clinical Practice

Please wait while the transcript is being prepared...
0:00
Hello, my name is Dr. John Frew. I'm a dermatologist and dermatological researcher based at the Department of Dermatology at Liverpool Hospital in Sydney, Australia. I will be speaking to you today regarding hidradenitis suppurativa or HS, including our current understanding of the pathophysiology, clinical features, and treatment of the disease.
0:23
These are some of my disclosures regarding work in HS, involvement in clinical trials and involvement in consulting work for various pharmaceutical and industry bodies.
0:37
First of all, today, I will be speaking to the pathophysiology of hidradenitis suppurativa. This is a complex and ever-evolving area of research and we understand a great deal more about the mechanisms involved in HS than we did even a few short years ago.
0:55
Clinically, hidradenitis suppurativa, also known as HS or acne inversa, is a chronic inflammatory disease that manifests in inflamed erythematous nodules, painful, malodorous draining tunnels, as well as fluctuant purulent abscesses with a predilection to flexural areas of skin. It has an extremely high disease burden and impact on quality of life. It affects individuals of all backgrounds and ages, but most commonly occurs in late adolescence or in individuals in their twenties. Although there certainly is some evidence to suggest that middle aged individuals are also prone to developing the disease. It is not an uncommon disease and has an estimated prevalence around 1 percent of the general population in all areas of the globe.

Quiz available with full talk access. Request Free Trial or Login.

Show
Hide

Hidradenitis suppurativa: current understanding and management

Embed in course/own notes